Melt-extrusion multiparticulates

Information

  • Patent Grant
  • 7510727
  • Patent Number
    7,510,727
  • Date Filed
    Tuesday, December 23, 2003
    20 years ago
  • Date Issued
    Tuesday, March 31, 2009
    15 years ago
Abstract
A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.
Description
BACKGROUND OF THE INVENTION

The present invention relates to a process of making granulates or multiparticulates which are useful, for example, in pharmaceutical dosage forms. In particular, the invention relates to a process for melt-extruding pharmaceutical agents with excipients to form multiparticulates suitable for inclusion in solid dosage forms such as capsules, tablets and the like.


It is known in the pharmaceutical art to prepare compositions which provide for controlled (slow) release of pharmacologically active substances contained in the compositions after oral administration to humans and animals. Such slow release compositions are used to delay absorption of a medicament until it has reached certain portions of the alimentary tract. Such sustained-release of a medicament in the alimentary tract further maintains a desired concentration of said medicament in the blood stream for a longer duration than would occur if conventional rapid release dosage forms are administered.


Over the years, several different methods of preparing controlled release pharmaceutical dosage forms have been suggested. For example, direct compression techniques, wet granulation techniques, encapsulation techniques and the like have been proposed to deliver pharmaceutically active ingredients to the alimentary tract over extended periods.


Melt granulation techniques have also been suggested to provide controlled release formulations. Melt granulation usually involves mechanically working an active ingredient in particulate form with one or more suitable binders and/or pharmaceutically acceptable excipients in a mixer until one or more of the binders melts and adheres to the surface of the particulate, eventually building up granules.


PCT International Publication No. WO 92/06679 discloses melt granulating methods for producing pellets containing therapeutically active substances. The method includes mechanically working a mixture containing the active substance in cohesive form with a binder having a melting point of 40-100° C., while supplying sufficient energy to melt the binder and form “overmoist” spherical pellets and thereafter adding an additional cohesive substance while maintaining the mechanical working to finally produce dry pellets.


PCT International Publication No. WO 93/18753 also discloses another melt extrusion process for preparing sustained-release pellets. This method includes pelletizing a mixture containing drug in finely divided form and a binder which includes one or more water-insoluble-wax-like binder substances with a melting point above 40° C. using a high shear mixer.


In the spite of the foregoing advances, a need for further alternatives in the field of controlled release formulations has been sought. The present invention addresses this need.


OBJECTS AND SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide improved methods for producing multiparticulates containing pharmaceutically active ingredients and excipients.


It is a further object of the present invention to provide multiparticulates containing pharmaceutically active ingredients which display improved controlled-release characteristics.


These objects and others have been accomplished by the present invention, which relates in part to a unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each of said particles comprising:

    • a) a therapeutically active agent;
    • b) one or more retardants; and
    • c) an optional water-insoluble binder.


      The particles have an average length of from about 0.1 to about 12 mm and the unit dose provides a release of the therapeutically active agent over at least about 8 hours.


Another aspect of the invention provides a method of preparing a multiparticulate sustained-release oral dosage form. This method includes mixing together a therapeutically effective agent, a water-insoluble retardant and an optional binder to form a homogeneous mixture, heating the mixture and thereafter extruding the mixture into strands. The strands are then cooled, and reduced to particles having a size of from about 0.1 to about 12 mm. This aspect further includes dividing the particles into unit doses. The ratio of water-insolube retardant material to therapeutically active agent is sufficient to impart a release of the active agent from the multiparticulate system over an extended time period. In this regard, the retardant will comprise about 5-95% of melt-extruded multiparticulate. The multiparticulate sustained-release system can be included within a hard gelatin capsule or other oral dosage forms such as a compressed tablet. Methods of preparing such dosage forms are also provided herein.


In yet a further aspect of the invention, there is provided a method of treating a patient with sustained-release multi-particulate formulations prepared as described above. This method includes administering a unit dose sustained release oral dosage form containing the novel melt-extruded particles to a patient in need of the active ingredient contained therein. For purposes of the present invention, a unit dose is understood to contain an effective amount of the therapeutically active agent.


A still further aspect of the invention provides an alternative method of preparing a multiparticulate sustained oral dosage form. This aspect includes directly metering into an extruder a homogeneous mixture of a water-insoluble retardant, a therapeutically active agent, and an optional binder, heating the homogeneous mixture, extruding said mixture to form strands, cooling the strands and cutting the strands into particles having a size of from about 0.1 to 12 mm and dividing the particles into unit doses. The ratio of hydrophobic material, namely water-insoluble retardant (and optional binder) to the therapeutically active agent is sufficient to impart a controlled release of the therapeutically active agent from the melt-extruded particles and unit doses over a time period of at least 8 hours.





BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims.



FIG. 1 is a graph displaying the dissolution results of Examples 1 and 2;



FIG. 2 is a graph displaying the dissolution rates of Examples 3-6;



FIGS. 3
a and 3b are graphs displaying the pH dependency of the dissolution results of Examples 3 and 5 respectively;



FIG. 4 is a graph displaying the dissolution results of Examples 7 and 8;



FIG. 5 is a graph displaying the dissolution results of Examples 9 and 10;



FIG. 6 is a graph displaying the dissolution results of Examples 11 and 12;



FIG. 7 is a graph displaying the dissolution results of Examples 13 and 14;



FIG. 8 is a schematic representation of a system for carrying out the present invention; and



FIG. 9 is a graph displaying the results of Example 15.





DETAILED DESCRIPTION

In accordance with the present invention, there are provided methods for preparing multiparticulates using melt-extrusion techniques and sustained release oral unit dosage forms containing a plurality of the melt extruded particulates. In accordance therewith, a therapeutically active agent is combined with one or more suitable controlled-release retardants, and optionally, a water-insoluble binder, extruded and thereafter rendered into a plurality of melt-extruded particles-or multiparticulates, such as spheres, beads or the like.


Pharmaceutical Agents


The active pharmaceutical agent(s) included in the controlled release multiparticulates of the present invention include systemically active therapeutic agents, locally active therapeutic agents, disinfecting agents, chemical impregnants, cleansing agents, deodorants, fragrances, dyes, animal repellents, insect repellents, a fertilizing agents, pesticides, herbicides, fungicides, and plant growth stimulants, and the like. The only limitation on the ingredient is that the pharmaceutical agent is capable of undergoing the inventive extrusion process without substantially losing its sought-after effect.


A wide variety of therapeutically active agents can be used in conjunction with the present invention. The therapeutically active agents (e.g. pharmaceutical agents) which may be used in the compositions of the present invention include both water soluble and water insoluble drugs. Examples of such therapeutically active agents include anti-histamines (e.g., dimenhydrinate, diphenhydramine, chlorpheniramine and dexchlorpheniramine maleate), analgesics (e.g., aspirin, codeine, morphine, dihydromorphone, oxycodone, etc.), non-steroidal anti-inflammatory agents (e.g., naproxyn, diclofenac, indomethacin, ibuprofen, sulindac), anti-emetics (e.g., metoclopramide), anti-epileptics (e.g., phenytoin, meprobamate and nitrezepam), vasodilators (e.g., nifedipine, papaverine, diltiazem and nicardirine), anti-tussive agents and expectorants (e.g., codeine phosphate), anti-asthmatics (e.g. theophylline), antacids, anti-spasmodics (e.g. atropine, scopolamine), antidiabetics (e.g., insulin), diuretics (e.g., ethacrynic acid., bendrofluazide), anti-hypotensives (e.g., propranolol, clonidine), antihypertensives (e.g, clonidine, methyldopa), bronchodilators (e.g., albuterol), steroids (e.g., hydrocortisone, triamcinolone, prednisone), anti-biotics (e.g., tetracycline), antihemorrhoidals, hypnotics, psychotropics, antidiarrheals, mucolytics, sedatives, decongestants, laxatives, vitamins, stimulants (including appetite suppressants such as phenylpropanolamine), as well as salts, hydrates, and solvates of the same. The above list is not meant to be exclusive.


In certain preferred embodiments, the multiparticulate systems of the present invention include one or more compounds known as opioid analgesics. Opioid analgesic compounds which may be used in the present invention include alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, salts thereof, mixtures of any of the foregoing, mixed mu-agonists/antagonists, mu-antagonist combinations, and the like.


In certain particularly preferred embodiments, the opioid analgesic is selected from morphine, codeine, hydromorphone, hydrocodone, oxycodone, dihydrocodeine, dihydromorphine, oxymorphone, hydrates and solvates of any of the foregoing, mixtures of any of the foregoing, and the like.


Controlled Release Retardants and Binders


According to the present invention, in order to obtain a controlled release of the active agent, the therapeutically active agent is homogeneously combined with a sufficient amount of a release-retardant material and, optionally, a water-insoluble binder prior to undergoing extrusion. The retardant can be a hydrophobic material such as a water-insoluble acrylic polymer or alkylcellulose, or a water soluble material such as hydroxyalkylcelluloses and related materials. If unit doses of the multiparticulate are to have about a 12 hour or shorter release pattern, hydroxyalkylcelluloses, for example will be extruded with the therapeutic agent. If release rates of greater than about 12 hours are desired, water-insoluble materials are selected. It is, of course, within the scope of the invention to have particles containing mixtures of the water soluble and insoluble polymers.


In certain preferred embodiments of the present invention, the hydrophobic polymer is a pharmaceutically acceptable acrylic polymer, including but not limited to acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cynaoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid) (anhydride), methyl methacrylate, polymethacrylate, poly(methyl methacrylate), poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, poly(methacrylic acid anhydride), and glycidyl methacrylate copolymers.


The melt-extruded particle will comprise from about 1 to about 99% by weight of the retardant and preferably from about 5 to 95% by weight. Other retardant polymers which may be used for the extrusion process of the present invention, as those skilled in the art will appreciate, include other cellulosic polymers, including other alkyl cellulosic polymers, may be substituted for part or all of water-insoluble portion of the retardant in the multiparticulate.


The terms “sustained release” and “extended duration” are defined for purposes of the present invention as the release of the drug (i.e., opioid analgesic) at such a rate that blood (e.g., plasma) levels are maintained within the therapeutic range but below toxic levels over a period of time greater than 6 hours, more preferably for periods of up to about 24 hours, or longer.


In certain preferred embodiments, the acrylic polymer is comprised of one or more ammonio methacrylate copolymers. Ammonio methacrylate copolymers are well known in the art, and are described in NF XVII as fully polymerized copolymers of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups.


In one preferred embodiment, the acrylic polymer is an acrylic resin lacquer such as that which is commercially available from Rohm Pharma under the Tradename Eudragit®. In further preferred embodiments, the acrylic polymer comprises a mixture of two acrylic resin lacquers commercially available from Rohm Pharma under the Tradenames Eudragit® RL30D and Eudragit® RS30D, respectively. Eudragit® RL30D and Eudragit® RS30D are copolymers of acrylic and methacrylic esters with a low content of quaternary ammonium groups, the molar ratio of ammonium groups to the remaining neutral (meth)acrylic esters being 1:20 in Eudragit® RL30D and 1:40 in Eudragit® RS30D. The mean molecular weight is about 150,000. Edragit® and Eudragit® L-100 are also preferred. The code designations RL (high permeability) and RS (low permeability) refer to the permeability properties of these agents. Eudragit® RL/RS mixtures are insoluble in water and in digestive fluids. However, multiparticulate systems formed to include the same are swellable and permeable in aqueous solutions and digestive fluids.


The polymers described above such as Eudragit® RL/RS may be mixed together in any desired ratio in order to ultimately obtain a sustained-release formulation having a desirable dissolution profile. Desirable sustained-release multiparticulate systems may be obtained, for instance, from 100% Eudragit® RL, 50% Eudragit® RL and 50% Eudragit® RS, and 10% Eudragit® RL:Eudragit® 90% RS. Of course, one skilled in the art will recognize that other acrylic polymers may also be used, such as, for example, Eudragit® L.


In other preferred embodiments, the hydrophobic polymer which may be used is a hydrophobic cellulosic material such as ethylcellulose. Those skilled in the art will appreciate that other cellulosic polymers, including other alkyl cellulosic polymers, may be substituted for part or all of the ethylcellulose included in the hydrophobic polymer portion of the multiparticulates of the present invention.


In certain preferred embodiments, the release-modifying agent or retardant is selected from materials such as hydroxyalkylcelluloses such as hydroxypropylmethylcellulose and mixtures of the foregoing.


The retardants may also include a plasticizer. Examples of suitable plasticizers for ethylcellulose include water insoluble plasticizers such as dibutyl sebacate, diethyl phthalate, triethyl citrate, tributyl citrate, and triacetin, although it is possible that other water-insoluble plasticizers (such as acetylated monoglycerides, phthalate esters, castor oil, etc.) may be used. Triethyl citrate is especially preferred.


Examples of suitable plasticizers for the acrylic polymers of the present invention include citric acid esters such as triethyl citrate NF XVI, tributyl citrate, dibutyl phthalate, and possibly 1,2-propylene glycol, polyethylene glycols, propylene glycol, diethyl phthalate, castor oil, and triacetin, although it is possible that other water-insoluble plasticizers (such as acetylated monoglycerides, phthalate esters, castor oil, etc.) may be used. Triethyl citrate is especially preferred.


The binder portion of the melt-extruded particles is optionally included. It has been fouond that the binder can be reduced or even eliminated from the extrusion if the physical properties and relationships between the therapeutically active ingredient and retardant(s) allow a sufficiently cohesive extruded strand to exit the apparatus. A non-limiting list of suitable binders includes hydrogenated vegetable or castor oil, paraffin, higher aliphatic alcohols, higher aliphatic acids, long chain fatty acids, fatty acid esters, and mixtures thereof.


The binder material may consist of one or more water-insoluble wax-like thermoplastic substances possibly mixed with one or more wax-like thermoplastic substances being less hydrophobic than said one or more water-insoluble wax-like substances. In order to achieve constant release, the individual wax-like substances in the binder material should be substantially non-degradable and insoluble in gastrointestinal fluids during the initial release phases.


Useful water-insoluble wax-like substances may be those with a water-solubility that is lower than about 1:5,000 (w/w).


Binder materials are preferably water-insoluble with more or less pronounced hydrophilic and/or hydrophobic trends. Specifically, the wax-like substance may comprise fatty alcohols, fatty acid esters, fatty acid glycerides (mono-, di-, and tri-glycerides), hydrogenated fats, hydrocarbons, normal waxes, stearic aid, stearyl alcohol and hydrophobic and hydrophilic polymers having hydrocarbon backbones.


In addition to the foregoing, the melt-extruded particles can be prepared to include pharmaceutically acceptable carriers and excipients. It is to be understood that these materials can be mixed with the particles after extrusion as well. Specific examples of pharmaceutically acceptable carriers and excipients that may be used to formulate oral dosage forms are described in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986), incorporated by reference herein. Techniques and compositions for making solid oral dosage forms are described in Pharmaceutical Dosage Forms: Tablets (Lieberman, Lachman and Schwartz, editors). Second Edition, published by Marcel Dekker, Inc., incorporated by reference herein. Techniques and compositions for making tablets (compressed and molded), capsules (hard and soft gelatin) and pills are also described in Remington's Pharmaceutical Sciences, (Arthur Osol, editor), 1553-1593 (1980), incorporated by reference herein.


An optional process for preparing the multiparticulates and unit doses of the present invention includes directly metering into an extruder a water-insoluble retardant, a therapeutically active agent, and an optional binder; heating said homogenous mixture; extruding said homogenous mixture to thereby form strands; cooling said strands containing said homogeneous mixture; and cutting said strands into particles having a size from about 0.1 mm to about 12 mm; and dividing said particles into unit doses. In this aspect of the invention, a relatively continuous manufacturing procedure is realized.


Multiparticulates and Multiparticulate Systems


The multiparticulate system can be, for example, in the form of granules, spheroids or pellets depending upon the extruder exit orifice. For purposes of the present invention, the terms “multiparticulate(s)” and “multiparticulate system(s)” and “melt-extruded paricles” shall refer to a plurality of units, preferably within a range of similar size and/or shape and containing one or more active agents and one or more excipients, preferably including a retardant as described herein. In this regard, the multiparticulates will be of a range of from about 0.1 to about 12 mm in length and have a diameter of from about 0.l to about 5 mm. In addition, it is to be understood that the multiparticulates can be any geometrical shape within this size range such as beads, microspheres, seeds, pellets, etc.


The multiparticulate can thereafter be included in a capsule or in any other suitable solid form.


The term “unit dose” is defined for purposes of the present invention as the total amount of substrates needed to administer a desired dose of drug (e.g., opioid analgesic) to a patient.


In one especially preferred embodiment, oral dosage forms are prepared to include an effective amount of multiparticulates within a capsule. For example, a plurality of the melt extruded particles may be placed in a gelatin capsule in an amount sufficient to provide an effective controlled-release dose when ingested and contacted by gastric fluid. In certain preferred embodiments of the present invention, the sustained-release multiparticulate systems are coated with a sustained-release coating. The coating formulations of the present invention should be capable of producing a strong, continuous film that is smooth and elegant, capable of supporting pigments and other coating additives, non-toxic, inert, and tack-free.


In order to obtain a sustained-release of opioid, for example, sufficient to provide an analgesic effect for the extended durations set forth in the present invention, the melt extruded particles comprising the therapeutically active agent may be coated with a sufficient amount of hydrophobic material to obtain a weight gain level from about 2 to about 30 percent, although the overcoat may be greater depending upon the physical properties of the particular opioid analgesic compound utilized and the desired release rate, among other things. In certain preferred embodiments of the present invention, the hydrophobic polymer comprising the sustained-release coating is a pharmaceutically acceptable acrylic polymer, such as those described hereinabove.


The solvent which is used for the hydrophobic material may be any pharmaceutically acceptable solvent, including water, methanol, ethanol, methylene chloride and mixtures thereof. It is preferable however, that the coatings be based upon aqueous dispersions of the hydrophobic material.


In one preferred embodiment the multiparticulate is used in a sustained-release opioid oral dosage form and includes hydromorphone as the therapeutically active ingredient in an amount from about 4 to about 64 mg hydromorphone hydrochloride. Alternatively, the dosage form may contain molar equivalent amounts of other hydromorphone salts or of the hydromorphone base. In other preferred embodiments where the opioid analgesic is other than hydromorphone, the dosage form contains an appropriate amount to provide a substantially equivalent therapeutic effect. For example, when the opioid analgesic comprises morphine, the sustained-release oral dosage forms of the present invention include form about 5 mg to about 800 mg morphine, by weight. When the opioid analgesic comprises oxycodone, the sustained-release oral dosage forms of the present invention include from about 5 mg to about 400 mg oxycodone. In these aspects of the invention, the multiparticulate can be encapsulated or compressed into solid oral dosage forms using standard techniques.


The unit dosage forms of the present invention may further include combinations of multiparticulates containing one or more of the active agents disclosed above before being encapsulated. Furthermore, the unit dosage forms can also include an amount of an immediate release active agent for prompt therapeutic effect.


The controlled-release formulations of the present invention slowly release the therapeutically active agent, e.g., when ingested and exposed to gastric fluids, and then to intestinal fluids. The controlled-release profile of the formulations of the invention can be altered, for example, by varying the amount of retardant, i.e., hydrophobic polymer, by varying the amount of plasticizer relative to hydrophobic polymer, by the inclusion of additional ingredients or excipients, by altering the method of manufacture, etc.


For example, hydromorphone-containing multiparticulate may also be overcoated with an aqueous dispersion of the hydrophobic polymer. The aqueous dispersion of hydrophobic polymer preferably further includes an effective amount of plasticizer, e.g. triethyl citrate. Pre-formulated aqueous dispersions of ethylcellulose, such as Aquacoat® or Surelease®, may be used. If Surelease® is used, it is not necessary to separately add a plasticizer. Alternatively, pre-formulated aqueous dispersions of acrylic polymers such as Eudragit® can be used. These coating solutions may also contain film-formers, plasticizers, a solvent system (i.e., water), a colorant to provide elegance and product distinction. Color may also be added to or during the extrusion of the therapeutically active agent and retardant.


The plasticized aqueous dispersion of hydrophobic polymer may be applied onto the multiparticulate comprising the therapeutically active agent by spraying using any suitable spray equipment known in the art. In a preferred method, a Wurster fluidized-bed system is used in which an air jet, injected from underneath, fluidizes the multiparticulate material and effects drying while the acrylic polymer coating is sprayed on. A sufficient amount of the aqueous dispersion of hydrophobic polymer to obtain a pre-determined controlled-release of said therapeutically active agent when the coated particulate is exposed to aqueous solutions, e.g. gastric fluid, is preferably applied, taking into account the physical characteristics of the therapeutically active agent, the manner of incorporation of the plasticizer, etc.


In addition to the above ingredients, a controlled-release matrix may also contain suitable quantities of other materials, e.g. diluents, lubricants, binders, granulating aids, colorants, flavorants and glidants that are conventional in the pharmaceutical art in amounts up to about 50% by weight of the particulate if desired.


In a further aspect of the present invention, a process for the preparation of a multiparticulate controlled release, oral dosage form is provided, This aspect includes homogeneously mixing a therapeutically effective agent with a water-insoluble retardant and, optionally, a binder; extruding the mixture, cooling the exiting extruded strands, rendering the strands into particles having a size of from about 0.1 to about 12 mm in length and optionally, encapsulating or compressing and shaping the granules into tablets. The diameter of the extruder aperture or exit port can also be adjusted to vary the thickness of the extruded strands. Furthermore, the exit part of the extruder need not be round; it can be oblong, rectangular, etc. The exiting strands can be reduced to particles using a hot wire cutter, guillotine, etc.


DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As shown in FIG. 8, a typical melt extrusion systems capable of carrying-out the present invention include a suitable extruder drive motor having variable speed and constant torque control, start-stop controls, and ammeter. In addition, the system will include a temperature control console which includes temperature sensors, cooling means and temperature indicators throughout the length of the extruder. In addition, the system will include an extruder such as twin-screw extruder which consists of two counter-rotating intermeshing screws enclosed within a cyclinder or barrel having an aperture or die at the exit thereof. The feed materials enter through a feed hopper and is moved through the barrel by the screws and is forced through the die into strands which are thereafter conveyed such as by a continuous movable belt to allow for cooling and being directed to a pelletizer or other suitable device to render the extruded ropes into the multiparticulate system. The pelletizer can consist of rollers, fixed knife, rotating cutter and the like. Suitable instruments and systems are available from distributors such as C.W. Brabender Instruments, Inc. of South Hackensack, N.J. Other suitable apparatus will be apparent to those of ordinary skill in the art.


General Pellet Manufacturing Procedure

Premix the required amount of drug, polymers, and optional binder (wax).


Charge a powder feeder with proper amount of drug/excipient blend.


Set temperatures of extruder to the required temperature, depending on the formulation. Wait until the corresponding heating zones reach steady temperatures. Start the feeder and the extruder. The drug/excipient powder blend is melted and intimately mixed in the extruder. The diameter of the extruder aperture can be adjusted to vary the thickness of the resulting strand.


Set the conveyor belt speed to an appropriate speed (e.g., 3-100 ft/min). Allow the extruded semisolid strand(s) to be congealed and transported to the pelletizer. Additional cooling devices may be needed to ensure proper congealing. (The conveyor belt may not be needed to cool the strand, if the material congeals rapidly enough.)


Set the roller speed and cutter speed (e.g., to 3-100 ft/min and 100-800 rpm). Cut the congealed strands to desired size (e.g., 3-5 mm in diameter, 0.3-5. mm in length).


Collect the pellet product.


Fill a desired weight of pellets into hard gelatin capsules to obtain an appropriate does of the drug.


Dissolution Method
(USP II Paddle at 100 rpm)

1st hour in 700 ml simulated gastric fluid or SGF thereafter, 900 ml simulated intestinal fluid SIF


Using HPLC procedures for assay


The following examples illustrate various aspects of the present invention. They are not meant to be construed to limit the claims in any manner whatsoever.


EXAMPLES 1-2

In these examples, chlorpheniramine maleate controlled release pellets were prepared according to the above manufacturing procedure using ethylcellulose and an acrylic polymer (Eudragit RSPO), respectively as the retardant. The formulations are set forth in Tables 1 and 2 below. The dissolution of these formulations is set forth in FIG. 1. Drug release rate from ethylcellulose pellets (prepared at 105° C.) is significantly slower than that from Eudragit RS pellets (prepared at 85° C.).









TABLE 1







EX. 1










Composition
Amt. (mg) per Capsule














Chlorpheniramine Maleate
60



Ethyl Cellulose
84



Stearic Acid
36



Total
180

















TABLE 2







EX. 2










Composition
Amt. (mg) per Capsule














Chlorpheniramine Maleate
60



Eudragit RSPO
84



Stearic Acid
36



Total
180










EXAMPLES 3-6
EX. 3

The excipients used in Ex. 2 were employed to make morphine sulfate controlled release pellets. The drug release rate was slower than expected especially during later hours of the dissolution.


EX. 4-6

To increase the drug dissolution rate during later hours, varying amounts of Eudragit L-100 were incorporated in the formulation. The drug dissolution rate increases with increasing amount of Eudragit L-100 in the formulation.









TABLE 3







EX. 3










Composition
Amt. (mg) per Capsule














Morphine Sulfate
60



Eudragit RSPO
42



Stearic Acid
18



Total
120

















TABLE 4







EX. 4










Composition
Amt. (mg) per Capsule














Morphine Sulfate
60



Eudragit RSPO
38.4



Eudragit L-100
3.6



Stearic Acid
18



Total
120

















TABLE 5







EX. 5










Composition
Amt. (mg) per Capsule














Morphine Sulfate
60



Eudragit RSPO
36



Eudragit L-100
6



Stearic Acid
18



Total
120

















TABLE 6







EX. 6










Composition
Amt. (mg) per Capsule














Morphine Sulfate
60



Eudragit RSPO
33.6



Eudragit L-100
8.4



Stearic Acid (SA)
18



Total
120










As seen in FIG. 3a, the drug dissolution rate obtained from the product of Ex. 3 showed a significant pH dependency. The release rate was slower in SIF (simulated intestinal fluid) than in SGF (simulated gastric fluid).


In FIG. 3b, it can be seen that due to the addition of Eudragit L-100, the drug dissolution rate obtained from Ex. 5 was less pH dependent. The drug release rate was faster in SIF during later hours of dissolution which is desirable for complete bioavailability.


EXAMPLES 7-8

As demonstrated in FIG. 4, with proper choice of plasticizers, the drug release rate from the formula containing Eudragit L-100 can be reduced. This may be necessary to achieve desirable plasma drug concentration profiles after oral administration of the pellets.









TABLE 7







EX. 7










Composition
Amt. (mg) per Capsule














Morphine Sulfate
60



Eudragit RSPO
33.6



Eudragit L-100
8.4



Stearic Acid (SA)
9



Diethyl Phthalate (DEP)
9



Total
120

















TABLE 8







EX. 8










Composition
Amt. (mg) per Capsule














Morphine Sulfate
60



Eudragit RSPO
33.6



Eudragit L-100
8.4



Stearic Acid (SA)
9



Tributyl Citrate (TBC)
9



Total
120










EXAMPLES 9-10

A different polymer/wax combination was used as an alternative formulation. As seen in FIG. 5, the drug dissolution rate from ethylcellulose/polyvinyl acetate phthalate was somewhat faster.









TABLE 9







EX. 9










Composition
Amt. (mg) per Capsule














Morphine Sulfate
60



Ethyl Cellulose
38.4



Polyvinyl Acetate Phthalate
3.6



Stearic Acid
18



Total
120

















TABLE 10







EX. 10










Composition
Amt. (mg) per Capsule














Morphine Sulfate
60



Ethyl Cellulose
34.8



Polyvinyl Acetate Phthalate
7.2



Stearic Acid
18



Total
120










EXAMPLES 11-12

The formula used in Ex. 5 was applied to oxycodone hydrochloride. Due to the higher potency of oxycodone, only 20 mg of drug was used. The missing 40 mg was replaced by 40 mg of talc (Ex. 12). No replacement was used in Ex. 11. When tested in only SGF or SIF, the use of Eudragit L causes the formulation to become less pH dependent. The results are shown in FIG. 6.









TABLE 11







EX. 11










Composition
Amt. (mg) per Capsule














Oxycodone Hydrochloride
20



Eudragit RSPO
36



Eudragit L-100
6



Stearic Acid
18



Total
120

















TABLE 12







EX. 12










Composition
Amt. (mg) per Capsule














Oxycodone Hydrochloride
20



Eudragit RSPO
36



Eudragit L-100
6



Stearic Acid
18



Talc
40



Total
120










EXAMPLES 13-14
Hydromorphone

The formula used in Ex. 5 was applied to hydromorphone hydrochloride. Due to the higher potency of hydromorphone, only 8 mg of drug was used. The missing 52 mg was replaced by 52 mg of talc (Ex. 14) or 52 mg of excipients (Ex. 13). The results are shown in FIG. 7.









TABLE 13







EX. 13










Composition
Amt. (mg) per Capsule














Hydromorphone Hydrochloride
8



Eudragit RSPO
67.2



Eudragit L-100
11.2



Stearic Acid
33.6



Total
120

















TABLE 14







EX. 14










Composition
Amt. (mg) per Capsule














Hydromorphone Hydrochloride
8



Eudragit RSPO
36



Eudragit L-100
6



Stearic Acid
18



Talc
52



Total
120










EXAMPLE 15

In this Example, a bioavailability study was under-taken. Fourteen subjects were given the morphine sulphate formulations of Example 3. The results are provided in Table 15 below and in FIG. 9.














TABLE 15







Group
AUC
Cmax
Tmax









Example 3 Fasted
230
15.7
2.1



Example 3 Fed
213
14.0
3.2










From the above data, it can be seen that the formulation is an ideal candidate for an extended release or once-a-day product without a food effect.


The examples provided above are not meant to be exclusive. Many other variations of the present invention would be obvious to those skilled in the art, and are contemplated to be within the scope of the appended claims.

Claims
  • 1. A unit dose sustained-release oral dosage form comprising a non-coated plurality of extruded particles, each of said particles consisting essentially of hydromorphone hydrochloride dispersed in a matrix comprising one or more hydrophobic retardants and one or more hydrophilic retardants; and a water insoluble binder; said particles being non-spheroidal and having a length from about 0.1 mm to about 12 mm and a diameter from about 0.1 mm to about 5 mm, said unit dose providing a release of said hydromorphone hydrochloride over at least about 6 hours.
  • 2. A sustained-release formulation comprising a non-coated plurality of extruded particles, each of said particles comprising hydromorphone hydrochloride dispersed in a matrix comprising one or more hydrophobic retardants selected from the group consisting of ethylcellulose and acrylic polymers and one or more hydrophilic retardants comprising hydroxyalkylcellulose; and a water insoluble binder selected from the group consisting of fatty alcohols, hydrogenated fats, fatty acid glycerides, hydrocarbons, waxes, hydrophobic and hydrophilic polymers having hydrocarbon backbones, fatty acid esters and mixtures thereof: said particles being non-spheroidal and having a length from about 0.1 mm to about 12 mm and a diameter from about 0.1 mm to about 5 mm and providing sustained release of hydromorphone hydrochloride over at least about 6 hours.
  • 3. The unit dose of claim 1, wherein said hydrophobic retardant is selected from the group consisting of ethylcellulose and acrylic polymers, and said hydrophilic retardant comprises hydroxyalkylcellulose.
  • 4. The unit dose of claim 3, wherein said acrylic polymer is comprised of monomers selected from the group consisting of an ester of acrylic acid, an ester of methacrylic acid, an alkyl ester of acrylic acid, an alkyl ester of methacrylic acid, and mixtures of any of the foregoing.
  • 5. The unit dose of claim 1, wherein said water insoluble binder is selected from the group consisting of fatty alcohols, hydrogenated fats, fatty acid esters, fatty acid glycerides, hydrocarbons, waxes, stearic acid, stearyl alcohol, and hydrophobic and hydrophilic polymers having hydrocarbon backbones, and mixtures thereof.
  • 6. The unit dose of claim 1, wherein said water insoluble binder is selected from the group consisting of stearyl alcohol, stearic acid, water-insoluble waxes, and mixtures thereof.
  • 7. The unit dose of claim 1, wherein said hydromorphone hydrochloride is present in an amount from about 2 mg to about 64 mg.
  • 8. A unit dose sustained-release oral dosage form comprising a non-coated plurality of extruded particles, each of said particles comprising: hydromorphone hydrochloride dispersed in a matrix comprising one or more hydrophobic retardants selected from the group consisting of acrylic polymers and alkylcelluloses and one or more hydrophilic retardants comprising hydroxyalkylcellulose; said particles being non-spheroidal and having a size from about 0.1 mm to about 12 mm and a diameter from about 0.1 mm to about 5 mm, said unit dose providing a release of said hydromorphone hydrochloride over at least about 6 hours.
  • 9. The unit dose of claim 8, wherein said acrylic polymer is comprised of monomers selected from the group consisting of an ester of acrylic acid, an ester of methacrylic acid, an alkyl ester of acrylic acid, an alkyl ester of methacrylic acid, and mixtures of any of the foregoing.
  • 10. The unit dose of claim 8, further comprising a water insoluble binder.
  • 11. The unit dose of claim 10, wherein said binder is selected from the group consisting of stearyl alcohol, stearic acid water insoluble waxes, fatty alcohols, hydrogenated fats, fatty acid esters, fatty acid glyercides, hydrocarbons, waxes, and hydrophobic and hydrophilic polymers having hydrocarbon backbones, and mixtures thereof.
  • 12. The unit dose of claim 8, wherein each of said particles comprise from about 1% to about 99% of said one or more retardants.
  • 13. The unit dose of claim 8, wherein each of said particles comprise from about 5% to about 95% of said one or more retardants.
  • 14. The unit dose of claim 8, wherein the diameter of said particles is from about 0.1 mm to about 3 cm.
  • 15. A unit dose sustained-release oral dosage form comprising a non-coated plurality of melt extruded particles, each of said particles comprising: (a) hydromorphone hydrochloride;(b) one or more hydrophobic retardants and one or more hydrophilic retardants; and(c) an optional water insoluble binder,said particles having a (length) size from about 0.1 mm to about 12 mm, said unit dose providing a release of said hydromorphone hydrochloride over at least about 6 hours.
  • 16. The dosage form of claim 15, wherein said hydrophobic retardant is an acrylic polymer, and said acrylic polymer is comprised of monomers selected from the group consisting of an ester of acrylic acid, an ester of methacrylic acid, an alkyl ester of acrylic acid, an alkyl ester of methacrylic acid, and mixtures of any of the foregoing.
  • 17. The dosage form of claim 15, wherein said water insoluble binder is selected from the group consisting of hydrogenated vegetable or castor oil, paraffin. higher aliphatic alcohols, higher aliphatic acids, long chain fatty acids, fatty acid esters, and mixtures thereof.
  • 18. The dosage form of claim 15, wherein said binder is selected from the group consisting of higher aliphatic alcohols and water-insoluble waxes.
  • 19. The dosage form of claim 15, wherein said particles have a diameter from about 0.1 to about 5 mm.
  • 20. The dosage form of claim 15, wherein each of said particles comprise from about 1% to about 99% of said retardant.
  • 21. The dosage form of claim 15, wherein each of said particles comprise from about 5% to about 95% of said retardant.
  • 22. The unit dose of claim 8, wherein said hydromorphone hydrochloride is present in an amount from about 2 mg to about 64 mg.
  • 23. The dosage form of claim 1, wherein each of said particles comprise from about 1% to about 99% of said retardant.
  • 24. The dosage form of claim 1, wherein each of said particles comprise from about 5% to about 95% of said retardant.
  • 25. The formulation of claim 2, wherein each of said particles comprise from about 1% to about 99% of said retardant.
  • 26. The formulation of claim 2, wherein each of said particles comprise from about 5% to about 95% of said retardant.
  • 27. The formulation of claim 2, wherein said hydromorphone hydrochloride is present in an amount from about 2 mg to about 64 mg.
  • 28. The unit does of claim 15, wherein said hydrophilic retardant comprises hydroxyalkylcellulose.
  • 29. The unit dose of claim 15, wherein said hydromorphone hydrochloride is present in an amount from about 2 mg to about 64 mg.
US Referenced Citations (138)
Number Name Date Kind
2738303 Blythe et al. Mar 1956 A
3065143 Christenson et al. Nov 1962 A
3652589 Flick et al. Mar 1972 A
3714350 Gough Jan 1973 A
3830934 Flick et al. Aug 1974 A
3845770 Theeuwes et al. Nov 1974 A
3853988 Casadio et al. Dec 1974 A
3880991 Yolles Apr 1975 A
3950508 Mony et al. Apr 1976 A
3965256 Leslie Jun 1976 A
3974157 Shetty et al. Aug 1976 A
4013784 Speiser Mar 1977 A
4076798 Casey et al. Feb 1978 A
4132753 Blichare et al. Jan 1979 A
4173417 Kruder Nov 1979 A
4230687 Sair et al. Oct 1980 A
4259314 Lowey Mar 1981 A
4265875 Byrne et al. May 1981 A
4292300 Byrne et al. Sep 1981 A
4310483 Dorfel et al. Jan 1982 A
4343789 Kawata et al. Aug 1982 A
4344431 Yolles Aug 1982 A
4346709 Schmitt Aug 1982 A
4366172 Lednicer Dec 1982 A
4374082 Hochschild Feb 1983 A
4380534 Fukui et al. Apr 1983 A
4389393 Schor et al. Jun 1983 A
4406883 Byrne et al. Sep 1983 A
4421736 Walters Dec 1983 A
4483847 Augart Nov 1984 A
4533562 Ikegami et al. Aug 1985 A
4613619 Sleigh et al. Sep 1986 A
4621114 Watanabe Nov 1986 A
4649042 Davis et al. Mar 1987 A
4720384 DiLuccio et al. Jan 1988 A
4764378 Keith et al. Aug 1988 A
4778676 Yang et al. Oct 1988 A
4801458 Hidaka et al. Jan 1989 A
4801460 Goertz et al. Jan 1989 A
4806337 Snipes et al. Feb 1989 A
4818450 Hall et al. Apr 1989 A
4828836 Elger et al. May 1989 A
4834984 Goldie et al. May 1989 A
4842761 Rutherford Jun 1989 A
4844907 Elger et al. Jul 1989 A
4844909 Goldie et al. Jul 1989 A
4861598 Oshlack Aug 1989 A
RE33093 Schiraldi et al. Oct 1989 E
4879108 Yang et al. Nov 1989 A
4880585 Klimesch et al. Nov 1989 A
4880830 Rhodes Nov 1989 A
4882151 Yang et al. Nov 1989 A
4882152 Yang et al. Nov 1989 A
4882153 Yang et al. Nov 1989 A
4882155 Yang et al. Nov 1989 A
4882156 Yang et al. Nov 1989 A
4882157 Yang et al. Nov 1989 A
4882159 Yang et al. Nov 1989 A
4882167 Jang Nov 1989 A
4894234 Sharma et al. Jan 1990 A
4917899 Geoghegan et al. Apr 1990 A
4925675 Giannini et al. May 1990 A
4935246 Ahrens Jun 1990 A
4957681 Klimesch et al. Sep 1990 A
4959208 Chakrabarti et al. Sep 1990 A
4967486 Doelling Nov 1990 A
4970075 Oshlack Nov 1990 A
4987136 Kreek et al. Jan 1991 A
4990341 Goldie et al. Feb 1991 A
4992100 Koepff et al. Feb 1991 A
4994227 Dietz et al. Feb 1991 A
5007790 Shell Apr 1991 A
5013306 Solomon et al. May 1991 A
5023089 Sakamoto et al. Jun 1991 A
5026560 Makino et al. Jun 1991 A
5030400 Danielson et al. Jul 1991 A
5035509 Kruder Jul 1991 A
5049394 Howard et al. Sep 1991 A
5055307 Tsuru et al. Oct 1991 A
5073379 Klimesch et al. Dec 1991 A
5102668 Eichel et al. Apr 1992 A
5126145 Evenstad Jun 1992 A
5132142 Jones et al. Jul 1992 A
5133974 Paradissis et al. Jul 1992 A
5162117 Stupak et al. Nov 1992 A
5165952 Solomon et al. Nov 1992 A
5167964 Muhammed et al. Dec 1992 A
5169645 Shukla et al. Dec 1992 A
5178868 Malmqvist-Granlund et al. Jan 1993 A
5183690 Carr et al. Feb 1993 A
5196203 Boehm Mar 1993 A
5202128 Morella et al. Apr 1993 A
5204119 Shiobara et al. Apr 1993 A
5225199 Oshlack et al. Jul 1993 A
5229148 Copper Jul 1993 A
5234697 Sipos Aug 1993 A
5240400 Fujimoto et al. Aug 1993 A
5262172 Sipos Nov 1993 A
5266331 Oshlack et al. Nov 1993 A
5271934 Goldberg et al. Dec 1993 A
5273758 Royce Dec 1993 A
5283065 Doyon et al. Feb 1994 A
5290560 Autant et al. Mar 1994 A
5292461 Juch et al. Mar 1994 A
5296266 Kunugi et al. Mar 1994 A
5300300 Egidio et al. Apr 1994 A
5330766 Morella et al. Jul 1994 A
5330768 Park et al. Jul 1994 A
5340581 Tseng et al. Aug 1994 A
5350584 McClelland et al. Sep 1994 A
5354856 Kawashima et al. Oct 1994 A
5356635 Raman et al. Oct 1994 A
5378462 Boedecker et al. Jan 1995 A
5380535 Geyer et al. Jan 1995 A
5395626 Kotwal et al. Mar 1995 A
5403593 Royce Apr 1995 A
5443846 Yoshioka et al. Aug 1995 A
5451424 Solomon et al. Sep 1995 A
5453283 Munch et al. Sep 1995 A
5456923 Nakamichi et al. Oct 1995 A
5472710 Klokkers-Bethke et al. Dec 1995 A
5472712 Oshlack et al. Dec 1995 A
5476528 Trimm et al. Dec 1995 A
5478577 Sackler et al. Dec 1995 A
5510114 Borella et al. Apr 1996 A
5516205 Oda et al. May 1996 A
5552159 Mueller et al. Sep 1996 A
5567439 Myers et al. Oct 1996 A
5622722 Knott et al. Apr 1997 A
5643773 Aebischer et al. Jul 1997 A
5700410 Nakamichi et al. Dec 1997 A
5958452 Oshlack Sep 1999 A
5965161 Oshlack et al. Oct 1999 A
6261599 Oshlack et al. Jul 2001 B1
6335033 Oshlack et al. Jan 2002 B2
6706281 Oshlack et al. Mar 2004 B2
6743442 Oshlack et al. Jun 2004 B2
20040081694 Oshlack et al. Apr 2004 A1
Foreign Referenced Citations (135)
Number Date Country
57224 May 1986 AU
8976091 Jun 1992 AU
2082573 May 1993 CA
2131350 Mar 1995 CA
2150304 Dec 1995 CA
2439538 Mar 1976 DE
3602360 Jul 1987 DE
3602370 Aug 1987 DE
3623193 Jan 1988 DE
4329794 Mar 1995 DE
0032004 Dec 1980 EP
0097523 Aug 1983 EP
0043254 May 1984 EP
0108218 May 1984 EP
0147780 Dec 1984 EP
0152379 Aug 1985 EP
0214735 Jul 1986 EP
0189861 Aug 1986 EP
204596 Dec 1986 EP
0204596 Dec 1986 EP
0208144 Jan 1987 EP
0248548 May 1987 EP
0249347 May 1987 EP
0251459 May 1987 EP
0253104 Jun 1987 EP
0240904 Oct 1987 EP
0240906 Oct 1987 EP
0254978 Feb 1988 EP
0256127 Feb 1988 EP
0267702 May 1988 EP
0271193 Jun 1988 EP
0275834 Jul 1988 EP
0300897 Jul 1988 EP
0021129 Sep 1988 EP
0295212 Dec 1988 EP
0327295 Aug 1989 EP
0337256 Oct 1989 EP
0068450 Jan 1990 EP
0351580 Jan 1990 EP
0377518 Jan 1990 EP
0354345 Feb 1990 EP
0358105 Mar 1990 EP
0358107 Mar 1990 EP
0361680 Apr 1990 EP
0361910 Apr 1990 EP
0368247 May 1990 EP
0375063 Jun 1990 EP
0377517 Jul 1990 EP
0298355 Nov 1990 EP
0415693 Mar 1991 EP
0430287 Jun 1991 EP
0463833 Jun 1991 EP
0241615 Sep 1991 EP
0452145 Oct 1991 EP
0239983 Nov 1991 EP
0465338 Jan 1992 EP
0481600 Apr 1992 EP
0531611 Apr 1992 EP
0240904 Jul 1992 EP
0535841 Sep 1992 EP
0320480 Nov 1992 EP
0337256 Nov 1992 EP
0526862 Feb 1993 EP
0338383 Mar 1993 EP
0529396 Mar 1993 EP
0533297 Mar 1993 EP
0534628 Mar 1993 EP
0544144 Jun 1993 EP
0546676 Jun 1993 EP
0667065 Aug 1993 EP
665010 Oct 1993 EP
0 574 894 Dec 1993 EP
0580860 Feb 1994 EP
580860 Feb 1994 EP
0582380 Feb 1994 EP
0624366 Apr 1994 EP
0595311 May 1994 EP
0249347 Jun 1994 EP
0436786 Jun 1994 EP
0636370 Feb 1995 EP
0491238 Mar 1995 EP
0642788 Mar 1995 EP
0609961 Aug 1995 EP
0205282 Sep 1995 EP
0624366 May 1996 EP
2273512 Jan 1976 FR
2273584 Jan 1976 FR
2642420 Mar 1990 FR
0997399 Apr 1964 GB
1405088 Jun 1971 GB
1504553 Mar 1978 GB
1513166 Jun 1978 GB
2030861 Apr 1980 GB
2111386 Dec 1982 GB
2117239 Mar 1983 GB
2053681 Apr 1984 GB
2196848 May 1988 GB
2207355 Jan 1991 GB
2246514 Feb 1992 GB
2281204 Mar 1995 GB
2284760 Jun 1995 GB
5257315 May 1977 JP
2223513 Sep 1990 JP
2223533 Sep 1990 JP
9218106 Oct 1992 JP
9104015 Apr 1991 WO
9119484 Dec 1991 WO
9119485 Dec 1991 WO
9201446 Feb 1992 WO
9202209 Feb 1992 WO
9205774 Apr 1992 WO
9206679 Apr 1992 WO
9222283 Dec 1992 WO
9300063 Jan 1993 WO
9300076 Jan 1993 WO
9304675 Mar 1993 WO
9307859 Apr 1993 WO
9307861 Apr 1993 WO
9310765 Jun 1993 WO
9317667 Sep 1993 WO
9318753 Sep 1993 WO
9324110 Dec 1993 WO
9403160 Feb 1994 WO
9403161 Feb 1994 WO
9405262 Mar 1994 WO
9408568 Apr 1994 WO
9422431 Oct 1994 WO
9423698 Oct 1994 WO
9423700 Oct 1994 WO
9514460 Jun 1995 WO
WO 03004029 Jan 2003 WO
WO 03004030 Jan 2003 WO
WO 03004031 Jan 2003 WO
WO 03004032 Jan 2003 WO
WO 03004033 Jan 2003 WO
Related Publications (1)
Number Date Country
20040185096 A1 Sep 2004 US
Continuations (3)
Number Date Country
Parent 10038867 Jan 2002 US
Child 10745950 US
Parent 09358828 Jul 1999 US
Child 10038867 US
Parent 08334209 Nov 1994 US
Child 09358828 US